OLER ABRAHAM N.
Known title: SVP Corp Dev & Gen CounselCIK: 0001557372
OLER ABRAHAM N.'s purchase track record
How the stock did after each of OLER ABRAHAM N.'s open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since September 28, 2021
Stock higher 6 months later
0%
3 months: 0%
Median 6-month return
-44.3%
3 months: -29.4%
Beat the S&P 500
0%
median -36.4% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/21/2022 | TRAW | $6K | -25.1% | -34.2% | -9.9% |
| 1/7/2022 | TRAW | $7K | -24.8% | -39.6% | -16.6% |
| 11/19/2021 | TRAW | $3K | -48.7% | -65.5% | -17.0% |
| 9/28/2021 | TRAW | $10K | -33.6% | -49.1% | +6.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| TRAW | ▲ Buy | Open Market | 1,500 | $3K | 1/28/2022 | View on chart |
| TRAW | ▲ Buy | Open Market | 1,500 | $3K | 1/21/2022 | View on chart |
| TRAW | ▲ Buy | Open Market | 1,500 | $3K | 1/14/2022 | View on chart |
| TRAW | ▲ Buy | Open Market | 1,500 | $4K | 1/7/2022 | View on chart |
| TRAW | ▲ Buy | Open Market | 1,000 | $3K | 11/19/2021 | View on chart |
| TRAW | ▼ Sell | Other | 5,000 | $15K | 11/18/2021 | View on chart |
| TRAW | ▲ Buy | Open Market | 2,381 | $10K | 9/28/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Traws Pharma listed in Benzinga health care movers
Traws Pharma was included in Benzinga's recent lists of health care stocks moving in pre-market and after-market sessions. These mentions indicate that the stock experienced price volatility relative to its peers during those trading periods. The company's shares currently trade near the middle of their 52-week range, with an average analyst target of $1.00.
Traws Pharma listed in Benzinga health care movers. Traws Pharma was included in Benzinga's recent lists of health care stocks moving in pre-market and after-market sessions. These mentions indicate that the stock experienced price volatility relative to its peers during those trading periods. The company's shares currently trade near the middle of their 52-week range, with an average analyst target of $1.00.